FDA OKs emergency use of AstraZeneca, J&J jabs to be donated by Japan, US | Inquirer News

FDA OKs emergency use of AstraZeneca, J&J jabs to be donated by Japan, US

By: - Reporter / @KAguilarINQ
/ 12:43 AM July 07, 2021

MANILA, Philippines — The Food and Drug Administration (FDA) has granted an emergency use authorization (EUA) to the Department of Health to accept the AstraZeneca and Johnson & Johnson COVID-19 vaccines to be donated by Japan and the United States, respectively.

“Regarding AstraZeneca, this is the second most widely used vaccine that we have now in our country. We recently issued an EUA to the Department of Health for them to be able to accept donations from Japan,” FDA Director-General Eric Domingo said, speaking party in Filipino, in a taped briefing with President Rodrigo Duterte that aired Wednesday.

Article continues after this advertisement

“Last week, we also issued an EUA to the Department of Health for possible donations coming from the USA of Janssen [from] Johnson & Johnson,” he added.

FEATURED STORIES

Japan aims to deliver the one million doses of AstraZeneca COVID-19 vaccine to the Philippines on July 8.

The Philippines also expects to receive up to one million doses of COVID-19 vaccines from the United States this month.

Secretary Carlito Galvez Jr., the country’s vaccine manager, previously said the US donation would likely be from Johnson & Johnson, a single-dose COVID-19 vaccine.

[atm]
Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

TAGS: AstraZeneca, Eric Domingo, EUA, FDA

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our newsletter!

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

© Copyright 1997-2024 INQUIRER.net | All Rights Reserved

This is an information message

We use cookies to enhance your experience. By continuing, you agree to our use of cookies. Learn more here.